CELU vs CLNN

Celularity Inc. vs Clene Inc. — Valuation Comparison 2026

CELU

Pharmaceutical Preparations
Celularity Inc.
Quality
4.9
out of 10
Value Trap
36
LOW
Price
$1.01
Last close
Models
7/13
Active
VS

CLNN

Pharmaceutical Preparations
Clene Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$6.56
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType CELU Fair ValueCELU Upside CLNN Fair ValueCLNN Upside
Bayesian DCF Intrinsic $1.10 -83.2%
Earnings Power Value Intrinsic $3.41 +256.8% $0.19 -97.0%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $3.98 +293.9% $8.12 +23.7%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CELU vs CLNN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CELU vs CLNN — Which Stock Is More Undervalued?

CELU scores higher with a 4.9/10 quality rating vs CLNN's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Celularity Inc. (CELU) and Clene Inc. (CLNN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CELU currently trades at $1.01 with a QOC of 4.9/10, while CLNN trades at $6.56 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).